Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Paul Ausick | Apr 15, 2014 at 8:30 AM EDT

Johnson & Johnson Earnings Point to New 52-Week High

Johnson & Johnson reported better-than-expected first-quarter results before markets opened Tuesday morning. And the company boosted its earnings guidance for…

Jon C. Ogg | Apr 10, 2014 at 11:33 AM EDT

Gilead Risks Beyond Just Merck: Serious Chart Violation Watch

Gilead Sciences may have been largely responsible for the drop in biotech stocks after politicians went after its drug costs,…

Trey Thoelcke | Apr 10, 2014 at 8:00 AM EDT

Who Bucked the Short Interest Trend in Biotech Stocks?

Thinkstock24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. Many biotech stocks pulled back…

Paul Ausick | Apr 7, 2014 at 11:15 AM EDT

Why Questcor Buyout Will Not Deter Short Sellers

The $5.6 billion acquisition of Questcor Pharmaceuticals by specialty drugmaker Mallinckrodt started the week off with a big bang. But…

Jon C. Ogg | Apr 7, 2014 at 11:00 AM EDT

FDA Keeps Driving Up Future Cost of Inhalable Insulin

While the FDA has been far from a friend to MannKind over the past few years, the latest FDA panel…

Trey Thoelcke | Apr 7, 2014 at 8:25 AM EDT

Credit Suisse Says Grit Your Teeth and Buy Biotech

In a new report, the Credit Suisse team says large cap biotech is cheaper than the S&P 500 on 2016…

Jon C. Ogg | Apr 4, 2014 at 8:30 AM EDT

Pancreatic Cancer Trial Enrollment Halt Damages Halozyme

Halozyme Therapeutics shares are getting pounded on Friday on news of a temporary halt of its Phase II trial enrollment…

Jon C. Ogg | Apr 4, 2014 at 8:20 AM EDT

Stifel Says Strong Earnings Will Reignite Biotech Rally

ThinkstockWhen the biotech sell-off started in late February, the stocks had been market leaders for almost four years. The staggering…

Douglas A. McIntyre | Apr 4, 2014 at 6:48 AM EDT

Boulder Ranks as America’s Thinnest City

ThinkstockBoulder, Colo., ranked as the city least plagued by obesity, according to recent research. Among the 10 cities with the…

Jon C. Ogg | Apr 3, 2014 at 10:50 AM EDT

Amgen Faces Cool Reception Over GSK Pact Termination

Amgen submitted an SEC Filing showing that, as of April 1, one of its subsidiaries and a GlaxoSmithKline subsidiary have…

Trey Thoelcke | Apr 3, 2014 at 8:30 AM EDT

Jefferies Biotech Stocks to Buy With Breakthrough Drug Innovations

New drug innovations are affecting the way that physicians treat such debilitating and deadly diseases as cancer. In a new…

Jon C. Ogg | Apr 2, 2014 at 3:37 PM EDT

Biotech Giants Now Priced Like Old World Drug Stocks

Most investors buying Big Pharma stocks these days are buying them for dividends and somewhat of a defensive position against…

Jon C. Ogg | Apr 2, 2014 at 8:20 AM EDT

Large Cap Biotechs Trading With Only Big Pharma P/E Ratios

In a new report from RBC, its analysts say that biotech stocks trading at some of the lowest forward multiples…

Jon C. Ogg | Apr 2, 2014 at 7:30 AM EDT

Can MannKind Shares Double Again on FDA Approval? (Final)

MannKind has a serious victory within its grasp. The company has struggled to get its Afrezza inhalable insulin to market…

Jon C. Ogg | Apr 1, 2014 at 6:06 PM EDT

Vindication for MannKind With FDA Panel Backing

ThinkstockMannKind Corp. (NASDAQ: MNKD)had been trading as though the stock was bracing for an U.S. Food and Drug Administration (FDA)…

1 … 289 290 291 292 293 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Johnson & Johnson Earnings Point to New 52-Week High

Gilead Risks Beyond Just Merck: Serious Chart Violation Watch

Who Bucked the Short Interest Trend in Biotech Stocks?

Why Questcor Buyout Will Not Deter Short Sellers

FDA Keeps Driving Up Future Cost of Inhalable Insulin

Credit Suisse Says Grit Your Teeth and Buy Biotech

Pancreatic Cancer Trial Enrollment Halt Damages Halozyme

Stifel Says Strong Earnings Will Reignite Biotech Rally

Boulder Ranks as America’s Thinnest City

Amgen Faces Cool Reception Over GSK Pact Termination

Jefferies Biotech Stocks to Buy With Breakthrough Drug Innovations

Biotech Giants Now Priced Like Old World Drug Stocks

Large Cap Biotechs Trading With Only Big Pharma P/E Ratios

Can MannKind Shares Double Again on FDA Approval? (Final)

Vindication for MannKind With FDA Panel Backing

Wall Street is Braced for Massive Inflation Numbers Wednesday Morning. Here’s What Numbers Could Cause Stocks to Sink or Soar.

3 Robotics Stocks in the M&A Spotlight in 2026

Forget VOO: Fidelity’s Tech ETF Is Up 29% While the Broad Market Lags

The Dividend Growth Path That Hauls in a Bigger Paycheck Than Your HR Rep

The 401(k) Bracket Smoothing Math: Why a 66 Year Old Couple With $1.5 Million Should Convert Exactly $90,000 a Year

Wall Street is Braced for Massive Inflation Numbers Wednesday Morning. Here’s What Numbers Could Cause Stocks to Sink or Soar.

3 Robotics Stocks in the M&A Spotlight in 2026

Health and Healthcare Articles

All Health and Healthcare Articles

Johnson & Johnson Earnings Point to New 52-Week High

Gilead Risks Beyond Just Merck: Serious Chart Violation Watch

Who Bucked the Short Interest Trend in Biotech Stocks?

Why Questcor Buyout Will Not Deter Short Sellers

FDA Keeps Driving Up Future Cost of Inhalable Insulin

Credit Suisse Says Grit Your Teeth and Buy Biotech

Pancreatic Cancer Trial Enrollment Halt Damages Halozyme

Stifel Says Strong Earnings Will Reignite Biotech Rally

Boulder Ranks as America’s Thinnest City

Amgen Faces Cool Reception Over GSK Pact Termination

Jefferies Biotech Stocks to Buy With Breakthrough Drug Innovations

Biotech Giants Now Priced Like Old World Drug Stocks

Large Cap Biotechs Trading With Only Big Pharma P/E Ratios

Can MannKind Shares Double Again on FDA Approval? (Final)

Vindication for MannKind With FDA Panel Backing

Wall Street is Braced for Massive Inflation Numbers Wednesday Morning. Here’s What Numbers Could Cause Stocks to Sink or Soar.

3 Robotics Stocks in the M&A Spotlight in 2026

Forget VOO: Fidelity’s Tech ETF Is Up 29% While the Broad Market Lags

Featured Reads

The Dividend Growth Path That Hauls in a Bigger Paycheck Than Your HR Rep

The 401(k) Bracket Smoothing Math: Why a 66 Year Old Couple With $1.5 Million Should Convert Exactly $90,000 a Year